Lataa...
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular activation, proliferation, effector function, and cell survival on binding to its ligand, CD70. Varlilumab, a novel, first-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates antitumor immunity a...
Tallennettuna:
| Julkaisussa: | Blood Adv |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7218437/ https://ncbi.nlm.nih.gov/pubmed/32380537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001079 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|